Impact of narcotic use on the requirement for colectomy in inpatients with ulcerative colitis

Diseases of the Colon and Rectum

Volumn 53, Issue 9, 2010, Pages 1295-1300

  Lian, Lei ^a,b   Fazio, Victor W ^a   Hammel, Jeffrey ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colectomy; Narcotic analgesics; Ulcerative colitis

Indexed keywords

ALBUMIN; CORTICOSTEROID; FENTANYL; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; MORPHINE; NALBUPHINE; NARCOTIC AGENT; OXYCODONE; PETHIDINE; ALBUMINOID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; COLON RESECTION; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT TRANSPORT; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; ULCERATIVE COLITIS; CHI SQUARE DISTRIBUTION; NONPARAMETRIC TEST; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ALBUMINS; CHI-SQUARE DISTRIBUTION; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NARCOTICS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77956646457     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181e7562c     Document Type: Article

References (29)

1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
2. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31:329-333.
3. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.
4. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515.
5. Kuriyama M, Kato J, Fujimoto T, et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum. 2006;49:1307-1315.
6. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004;19: 1247-1252.
7. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks ofulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-835.
8. Ananthakrishnan AN, Issa M, Beaulieu DB, et al. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15: 176-181.
9. Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37:418-423.
10. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345-351.
11. Palm O, Moum B, Jahnsen J, et al. Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. J Rheumatol. 2001;28:590-594.
12. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001;16:1235-1238.
13. Gingold BS. Stercoral ulceration and perforation of colon secondary to narcotics abuse. Am J Proctol Gastroenterol Colon Rectal Surg. 1981;32:5-6, 24.
14. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
15. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;11:2363-2371.
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-ami-nosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625-1629.
17. Garrett JM, Sauer WG, Moertel CG. Colonic motility in ulcerative colitis after opiate administration. Gastroenterology. 1967; 53:93-100.
18. Boyd CA. Opiates and intestinal secretion. Lancet. 1976;2:1085.
19. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. NeurosciLett. 2004;361:192-195.
20. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
21. Plant OH, Miller GH. The effect ofmorphine and some of the other opium alkaloids on the muscular activity of the alimentary canal. IV. Action of morphine on the colon of unanesthetized dogs and man. J Pharmacol Exp Ther. 1928;32:437-450.
22. Garrett JM, Sauer WG, Moertel CG. Colonic motility in ulcerative colitis after opiate administration. Gastroenterology. 1967; 53:93-100.
23. Hartong WA, Arvanitakis C, Skibba RM, Klotz AP. Treatment of toxic megacolon: a comparative review of 29 patients. Am J Dig Dis. 1977;22:195-200.
24. Smith FW, Law DH, Nickel WF Jr, Sleisenger MH. Fulminant ulcerative colitis with toxic dilation of the colon: medical and surgical management ofeleven cases with observations regarding etiology. Gastroenterology. 1962;42:233-243.
25. Cone JB, Wetzel W. Toxic megacolon secondary to pseudomembranous colitis. Dis Colon Rectum. 1982;25:478-482.
26. Templeton JL. Toxic megacolon complicating pseudomembranous colitis. Br J Surg. 1983;70:48.
27. Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol. 1985;7:137-143.
28. Caprilli R, Latella G, Vernia P, et al. Multiple organ dysfunction in ulcerative colitis. Am J Gastroenterol. 2000;95:1258-1262.
29. Silverberg D, Rogers AG. Toxic megacolon in ulcerative colitis. Can Med Assoc J. 1964;90:357-363.